AAAAAA

   
Results: 1-25 | 26-50 | 51-69 |
Results: 51-69/69
Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different?
Authors: Turkstra, F Karemaker, R Kuijer, PMM Prins, MH Buller, HR
Citation: F. Turkstra et al., Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different?, THROMB HAEM, 81(3), 1999, pp. 345-348
Incidence of venous thromboembolism in families with inherited thrombophilia
Authors: Simioni, P Sanson, BJ Prandoni, P Tormene, D Friederich, PW Girolami, B Gavasso, S Huisman, MV Buller, HR ten Cate, JW Girolami, A Prins, MH
Citation: P. Simioni et al., Incidence of venous thromboembolism in families with inherited thrombophilia, THROMB HAEM, 81(2), 1999, pp. 198-202
Prevention of deep vein thrombosis after hip replacement - Comparison between two low-molecular-weight heparins, tinzaparin and enoxaparin
Authors: Planes, A Samama, MM Lensing, AWA Buller, HR Barre, J Vochelle, N Beau, B
Citation: A. Planes et al., Prevention of deep vein thrombosis after hip replacement - Comparison between two low-molecular-weight heparins, tinzaparin and enoxaparin, THROMB HAEM, 81(1), 1999, pp. 22-25
In vivo treatment of rats with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) does not affect experimentally induced colon carcinoma metastasis
Authors: Smorenburg, SM Vink, R te Lintelo, M Tigchelaar, W Maas, A Buller, HR van Noorden, CJF
Citation: Sm. Smorenburg et al., In vivo treatment of rats with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) does not affect experimentally induced colon carcinoma metastasis, CLIN EXP M, 17(5), 1999, pp. 451-456
Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study
Authors: Rosing, J Middeldorp, S Curvers, J Thomassen, MCLGD Nicolaes, GAF Meijers, JCM Bouma, BN Buller, HR Prins, MH Tans, G
Citation: J. Rosing et al., Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study, LANCET, 354(9195), 1999, pp. 2036-2040
Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints
Authors: Levi, M Cromheecke, ME de Jonge, E Prins, MH de Mol, BJM Briet, E Buller, HR
Citation: M. Levi et al., Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints, LANCET, 354(9194), 1999, pp. 1940-1947
Deep-vein thrombosis
Authors: Lensing, AWA Prandoni, P Prins, MH Buller, HR
Citation: Awa. Lensing et al., Deep-vein thrombosis, LANCET, 353(9151), 1999, pp. 479-485
Differences in intima-media thickness in the carotid and femoral arteries in familial hypercholesterolemic heterozygotes with and without clinical manifestations of cardiovascular disease
Authors: Wittekoek, ME de Groot, E Prins, MH Trip, MD Buller, HR Kastelein, JJP
Citation: Me. Wittekoek et al., Differences in intima-media thickness in the carotid and femoral arteries in familial hypercholesterolemic heterozygotes with and without clinical manifestations of cardiovascular disease, ATHEROSCLER, 146(2), 1999, pp. 271-279
Oral contraceptives and hormonal replacement therapy cause an imbalance incoagulation and fibrinolysis which may explain the increased risk of venous thromboembolism
Authors: Levi, M Middeldorp, S Buller, HR
Citation: M. Levi et al., Oral contraceptives and hormonal replacement therapy cause an imbalance incoagulation and fibrinolysis which may explain the increased risk of venous thromboembolism, CARDIO RES, 41(1), 1999, pp. 21-24
Double-homozygosity for factor V Leiden and the prothrombin gene G20210A variant in a young patient with idiopathic venous thrombosis
Authors: Meinardi, JR Pelsma, PM Koning, H van der Meer, J Middeldorp, S Buller, HR Hamulyak, K
Citation: Jr. Meinardi et al., Double-homozygosity for factor V Leiden and the prothrombin gene G20210A variant in a young patient with idiopathic venous thrombosis, BLOOD, 94(5), 1999, pp. 1828-1829
The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: A prospective cohort study
Authors: Sanson, BJ Simioni, P Tormene, D Moia, M Friederich, PW Huisman, MV Prandoni, P Bura, A Rejto, L Wells, P Mannucci, PM Girolami, A Buller, HR Prins, MH
Citation: Bj. Sanson et al., The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: A prospective cohort study, BLOOD, 94(11), 1999, pp. 3702-3706
Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism
Authors: Kuijer, PMM Hutten, BA Prins, MH Buller, HR
Citation: Pmm. Kuijer et al., Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism, ARCH IN MED, 159(5), 1999, pp. 457-460
Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl - A meta-analysis
Authors: Girolami, B Bernardi, E Prins, MH ten Cate, JW Hettiarachchi, R Prandoni, P Girolami, A Buller, HR
Citation: B. Girolami et al., Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl - A meta-analysis, ARCH IN MED, 159(4), 1999, pp. 337-345
Risk of venous thrombosis with use of current low-dose oral contraceptivesis not explained by diagnostic suspicion and referral bias
Authors: Bloemenkamp, KWM Rosendaal, FP Buller, HR Helmerhorst, FM Colly, LP Vandenbroucke, JP
Citation: Kwm. Bloemenkamp et al., Risk of venous thrombosis with use of current low-dose oral contraceptivesis not explained by diagnostic suspicion and referral bias, ARCH IN MED, 159(1), 1999, pp. 65-70
Increased risk for fetal loss in carriers of the factor V Leiden mutation
Authors: Meinardi, JR Middeldorp, S de Kam, PJ Koopman, MMW van Pampus, ECM Hamulyak, K Prins, MH Buller, HR van der Meer, J
Citation: Jr. Meinardi et al., Increased risk for fetal loss in carriers of the factor V Leiden mutation, ANN INT MED, 130(9), 1999, pp. 736-739
Low-molecular-weight heparin for treating venous thromboembolism - Response
Authors: Koopman, MMW Buller, HR
Citation: Mmw. Koopman et Hr. Buller, Low-molecular-weight heparin for treating venous thromboembolism - Response, ANN INT MED, 130(1), 1999, pp. 77-78
High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia
Authors: van Pampus, MG Dekker, GA Wolf, H Huijgens, PC Koopman, MMW von Blomberg, BME Buller, HR
Citation: Mg. Van Pampus et al., High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia, AM J OBST G, 180(5), 1999, pp. 1146-1150
Diagnostic management of venous thromboembolism
Authors: Kraaijenhagen, RA Lensing, AWA Wallis, JW van Beek, EJR ten Cate, JW Buller, HR
Citation: Ra. Kraaijenhagen et al., Diagnostic management of venous thromboembolism, BAIL CLIN H, 11(3), 1998, pp. 541-586
Outpatient therapy with low-molecular-weight heparins: New perspectives for treatment of deep vein thrombosis
Authors: Buller, HR
Citation: Hr. Buller, Outpatient therapy with low-molecular-weight heparins: New perspectives for treatment of deep vein thrombosis, HAEMOSTASIS, 28, 1998, pp. 91-94
Risultati: 1-25 | 26-50 | 51-69 |